The company intends to use the funds to support the pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, an expansion study in children and adolescents up to 18 years of age, commercial scale-up of internal GMP manufacturing capabilities, and pipeline advancement, including ETX301 toward a 2027 IND submission for post-amputation neuroma pain.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

341 Oyster Point Blvd.
San Francisco, CA 94080
USA

Phone

(650) 491-0272

Website

www.encoded.com

Email Address

[email protected]

Overview

Encoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.

Profile

Social Media

Encoded Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Sean Nolan

Chief Executive Officer

Kartik Ramamoorthi

Chief Medical Officer

Salvador Rico

Chief Operating Officer

David Oberkofler

Chief Scientific Officer

Stephanie Tagliatela

Chief Technical Officer

Martin Moorhead

VP - Bus. Development

David McNinch

VP - Human Resources

Monique Bobadilla

VP - Manufacturing

Andrew Stober

VP - Regulatory Affairs

Nancy Boman

Browse more venture capital transactions:

Prev: 9/9/2026: Allogenetics venture capital transaction
Next: 9/9/2026: Rebaba venture capital transaction

Share this article

News on VC Transactions

We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary